Nomura India maintained its 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. Cipla anticipates ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

Pharma major Cipla will release its Q4 FY25 earnings on May 13, 2025. The Board may also consider a final dividend for FY25.

OKLAHOMA CITY -- — Shai Gilgeous-Alexander had 27 points and 12 assists in just 27 minutes, and the Oklahoma City Thunder rolled to a 145-117 victory over the Chicago Bulls on Monday night for ...

The difference between the best tablets and the worst can be stark. Our tough independent tests weed out the models to avoid and our expert buying advice will help you choose a winner. Use the results ...

"If we formulate these products into familiar dosage forms such as tablets, we add more value to these earlier products and make them accessible to the general public,” he added. The pill, named as ...

5G tablets offer seamless connectivity, making them ideal for work, entertainment, and communication. With larger screens than smartphones, they provide an immersive experience for streaming ...

Cipla is currently trading at Rs 1511.15, showing a decline of 0.85% today, with a trading volume of 927,691 shares. Cipla's stock is currently valued at Rs 1511.9, reflecting a decrease of 0.8% today ...

If you’re on the hunt for the ultimate portable gaming machine in 2025, tablets are no longer just large-screen companions for streaming and browsing — they’ve become powerful gaming devices ...

In an alarming new look at banking across America, 145 bank branches have closed in only a few weeks. Mitrade is reporting that between February 7 and March 14, several banks notified the U.S ...

There’s a fingerprint scanner built into the power button that proved quite unreliable, the battery drained pretty quickly during gaming, and the tablet could heat up quite a bit. I also found ...

Taipei: Taiwan-based Formosa Pharmaceuticals has announced an exclusive licensing agreement with Cipla Limited for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007 ...